Rasburicase-Induced Methemoglobinemia

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• Methemoglobinemia is a condition where hemoglobin's iron is oxidized, impairing oxygen transport.
• Rasburicase, an enzyme for tumor lysis syndrome, is associated with rare methemoglobinemia.
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a key risk factor.

Observation:

• Methemoglobinemia is a rare complication of rasburicase treatment.
• Patients with G6PD deficiency are particularly susceptible.
• Methylene blue is a standard treatment for methemoglobinemia.

Findings:

• In G6PD-deficient individuals, methylene blue is not effectively metabolized.
• This ineffective metabolism can exacerbate hemoglobin oxidation, worsening methemoglobinemia.
• Methylene blue can induce hemolysis in G6PD-deficient patients.

Implications:

• Methylene blue should be avoided in patients with G6PD deficiency undergoing rasburicase treatment.
• Alternative treatments for methemoglobinemia may be necessary in this population.
• Understanding this drug interaction is crucial for patient safety and effective clinical management.